This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Subscribe To Our Newsletter & Stay Updated
